BiotechTube
Home/Pipeline/GRC 65327

GRC 65327

Oncology (unspecified)

PreclinicalActive

Key Facts

Indication
Oncology (unspecified)
Phase
Preclinical
Status
Active
Company
Ichnos Glenmark Innovation

About Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) is a private, clinical-stage biotech advancing a pipeline of novel multispecific antibodies for oncology, powered by its proprietary BEAT® protein engineering platform. Its lead asset, ISB 2001, is a trispecific T-cell engager in Phase 1b for multiple myeloma, with additional preclinical programs targeting immune modulation. The company is led by an experienced management team with deep oncology drug development expertise and operates from innovation centers in the USA, Switzerland, and India.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a
DDX3 Inhibitor (Oncology)Lead Discovery SienaDiscovery